|
1）Levin A, Stevens PE. Summary of KDIGO guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014; 85: 49-61
|
|
|
|
2）Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005; 294: 813-8
|
|
|
|
|
|
3）Chawla LS, Kimmel PL. Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int. 2012; 82: 516-24
|
|
|
|
|
|
4）Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003; 41: 1-12
|
|
|
|
|
|
5）Rule AD, Amer H, Cornell LD, et al. The association between age and nephrosclerosis on renal biopsy among healthy adults. Ann Intern Med. 2010; 152: 561-7
|
|
|
|
|
|
6）Hsu CY, Iribarren C, McCulloch CE, et al. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009; 169: 342-50
|
|
|
|
|
|
7）Fontana L, Partridge L, Longo VD. Extending healthy life span--from yeast to humans. Science. 2010; 328: 321-6
|
|
|
|
|
|
8）Guarente L. Franklin H. Epstein Lecture: Sirtuins, aging, and medicine. N Engl J Med. 2011; 364: 2235-44
|
|
|
|
|
|
9）Kitada M, Kume S, Koya D. Role of sirtuins in kidney disease. Curr Opin Nephrol Hypertens. 2014; 23: 75-9
|
|
|
|
|
|
10）Kitada M, Kume S, Takeda-Watanabe A, et al. Sirtuins and renal diseases: relationship with aging and diabetic nephropathy. Clin Sci (Lond). 2013; 124: 153-64
|
|
|
|
|
|
11）Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis. 1992; 20: 1-17
|
|
|
|
|
|
12）Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119: 1420-8
|
|
|
|
|
|
13）Yuan Y, Chen Y, Zhang P, et al. Mitochondrial dysfunction accounts for aldosterone-induced epithelial-to-mesenchymal transition of renal proximal tubular epithelial cells. Free Radic Biol Med. 2012; 53: 30-43
|
|
|
|
|
|
14）Li J, Qu X, Ricardo SD, et al. Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deacetylation of Smad3. Am J Pathol. 2010; 177: 1065-71
|
|
|
|
|
|
15）He W, Wang Y, Zhang MZ, et al. Sirt1 activation protects the mouse renal medulla from oxidative injury. J Clin Invest. 2010; 120: 1056-68
|
|
|
|
|
|
16）Hasegawa K, Wakino S, Yoshioka K, et al. Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression. Biochem Biophys Res Commun. 2008; 372: 51-6
|
|
|
|
|
|
17）Hasegawa K, Wakino S, Yoshioka K, et al. Kidney-specific overexpression of Sirt1 protects against acute kidney injury by retaining peroxisome function. J Biol Chem. 2010; 285: 13045-56
|
|
|
|
|
|
18）Kim DH, Jung YJ, Lee JE, et al. SIRT1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53. Am J Physiol Renal Physiol. 2011; 301: F427-35
|
|
|
|
|
|
19）Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008; 132: 344-62
|
|
|
|
|
|
20）Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004; 23: 2369-80
|
|
|
|
|
|
21）Kitada M, Takeda A, Nagai T, et al. Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of Sirt1 in diabetic Wistar fatty (fa/fa) rats: a model of type 2 diabetes. Exp Diabetes Res. 2011; 2011: 908185
|
|
|
|
|
|
22）Jung YJ, Lee JE, Lee AS, et al. SIRT1 overexpression decreases cisplatin-induced acetylation of NF-kappaB p65 subunit and cytotoxicity in renal proximal tubule cells. Biochem Biophys Res Commun. 2012; 419: 206-10
|
|
|
|
|
|
23）Rabadi MM, Xavier S, Vasko R, et al. High-morbility group box 1 is a novel deacetylation target of Sirtuin 1. Kidney Int. 2014. [Epub ahead of print]
|
|
|
|
|
|
24）Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell. 2010; 40: 280-93
|
|
|
|
|
|
25）Tanaka Y, Kume S, Kitada M, et al. Autophagy as a therapeutic target in diabetic nephropathy. Exp Diabetes Res. 2012; 2012: 628978
|
|
|
|
|
|
26）Kume S, Uzu T, Horiike K, et al. Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J Clin Invest. 2010; 120: 1043-55
|
|
|
|
|
|
27）Miyazaki R, Ichiki T, Hashimoto T, et al. SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2008; 28: 1263-9
|
|
|
|
|
|
28）Zhang D, Li S, Cruz P, et al. Sirtuin 1 functionally and physically interacts with disruptor of telomeric silencing-1 to regulate alpha-ENaC transcription in collecting duct. J Biol Chem. 2009; 284: 20917-26
|
|
|
|
|
|
29）Hasegawa K, Wakino S, Simic P, et al. Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat Med. 2013; 19: 1496-504
|
|
|
|
|
|
30）Zhou X, Fan LX, Sweeney WE Jr, et al. Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease. J Clin Invest. 2013; 123: 3084-98
|
|
|
|
|
|
31）Koyama T, Kume S, Koya D, et al. SIRT3 attenuates palmitate-induced ROS production and inflammation in proximal tubular cells. Free Radic Biol Med. 2011; 51: 1258-67
|
|
|
|
|